10:30 AM
 | 
Nov 30, 2018
 |  BC Week In Review  |  Financial News  |  Completed Offerings

Inflazome to bring inflammasome inhibitors to clinic with €40M series B

Inflazome Ltd. (Dublin, Ireland) raised €40 million ($45.7 million) in a series B round on Nov. 19, giving it the funds to take several of its inflammasome inhibitors to the clinic next year, including a Parkinson's disease candidate.

New investors Forbion and Longitude Capital led the round; founding investors Novartis...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >